A Prospective, Multicentre, Non-Controlled, Observational, 52-Weeks Study: the Evaluation of the Body Weight Progress During the Treatment With Insulin Detemir in Type 1 or 2 Diabetes Patients, Previously Treated With Other Basal Insulins.
Phase of Trial: Phase IV
Latest Information Update: 18 Aug 2014
At a glance
- Drugs Insulin detemir (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms KILOS
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2012 Planned end date changed from 1 Nov 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.